anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A compound expressed by formula I (R<1> is lower alkyl, lower alkoxyl, halogen, etc.; R<2> is H or lower alkyl which may have a substituent group; n is 0, 1 or 2; m is 1 or 2) and a salt thereof. EXAMPLE:2-[4-( 1-Methyl-cis-4-tert-butylcyclohexyloxy )anilino]-3-( 4-methoxyphenyl)propionic acid. USE:Having the increasing action on high-density lipoprotein (HDL) cholesterol, and useful for treatment and prevention of arteriosclerosis. PREPARATION:A compound expressed by formula II is reacted with a compound expressed by formula III in the presence of a strong base, e.g. metallic sodium, to give a compound expressed by formula IV, and the nitro group of the resultant compound expressed by formula IV is reduced to form a compound expressed by formula V. The resultant compound expressed by formula V is then reacted with an alpha-halogeno-alpha-substituted acetic acid derivative expressed by formula VI in the presence of a deacidifying agent, e.g. pyridine, to afford the aimed compound expressed by formula I .
PURPOSE: Immunodysregulation, Polyendocrinopathy, Enteropathy, and X-linked syndrome (IPEX), caused by pathogenic FOXP3 variants, is a rare autoimmune disorder with diverse clinical features, including early-onset diabetes, eczema, and enteropathy. Atypical cases show milder symptoms and unique signs, requiring different treatments. Therefore, there are ambiguities in the accurate diagnosis and management of IPEX. We sought to present clinical, genetic, and immunological assessments of 12 IPEX patients with long-term follow-up to facilitate the diagnosis and management of the disease.
METHODS: Clinical findings and treatment options of the patients were collected over time. Lymphocyte subpopulations, protein expressions, regulatory T (Treg) and circulating T follicular helper (cTFH) cells, and T-cell proliferation were analyzed.
RESULTS: Predominant presentations included autoimmunity (91.6%), failure to thrive (66.7%), and eczema (58.3%). There were four classical and eight atypical IPEX individuals. Allergic manifestations were more common in atypical patients. Notably, chronic diarrhea demonstrated heightened severity compared to other manifestations. Four patients (33.3%) demonstrated eosinophilia, and nine (75%) showed high serum IgE levels. Most patients exhibited normal percentages of Treg cells with reduced CD25, FOXP3, and CTLA-4 expressions, corrected after hematopoietic stem cell transplantation (HSCT). Compared to healthy controls, the TH2-like skewing accompanied by reduced TH17-like responses was observed in cTFH and Treg cells of patients. Overall, nine patients (75%) received immunosuppressants (ISs), and six (50%) underwent HSCT, which was the only treatment revealing sustained control. Sirolimus was used in six patients and showed better control than other ISs.
CONCLUSIONS: The first cohort from Turkey with long-term follow-up results, comparing typical and atypical cases, provides insights into the outcomes of different therapeutic modalities and T- cell subtype changes in IPEX syndrome.
Study patients are treated with albumin dialysis (Molecular Adsorbents recirculating system), based on the clinical judgement by the treating physician. Of the 20 patients, two did not need MARS and the rest received MARS treatment with varying treatment cycles.
The present invention relates to a light curing composite resin for oral cavities, which comprises resins and stuffing. The resins are prepared from 2.5 to 20 wt% of super cladodification polyester-HPIP-A, 20 to 50 wt % of bisphenol A dimethyl acrylic acid glycidyl ester (BisGMA), 35 to 60 wt% of dimethyl acrylic acid diglycidyl triethylene glycol ester (TEGDMA), 0.25 to 2.5 wt% of camphorquinone (CQ) used as an initiator and 0.25 to 2.5 wt% of N, N-dimethyl ethyl acrylate (DMAEMA) used as a coinitiator. The stuffing is powdered glass 8235 made by a Schott company (Germany), and the weight of the stuffing accounts for 65 to 80 % of the total weight of the composite resins. In the preparation method, the HPIP-A, the BisGMA and the TEGDMA are uniformly stirred and mixed in a water bath at the temperature of 45 to 55 DEG C, and the CQ and the DMAEMA are added to be uniformly mixed; then, the mixture is filled into a brown bottle to be placed at the temperature of 4 to 10 DEG C in darkness for more than 24 hours, and the CQ is dissolved sufficiently. 20 to 35 wt% of resin is added to 65 to 80 wt% of Schott powdered glass 8235 to be uniformly mixed, and the mixture is put into a vacuum drying oven for 12 to 24 hours to remove gas bubbles. Thus, the composite resins for oral cavities are obtained.
This is a single arm purely qualitative (interview only) study with no comparator. All participants will use the FreeStyle Precision Neo-Meter for at least 3 months for self-monitoring of their blood glucose.
Tinnitus and posttraumatic stress disorder (PTSD) are two of the most common service-connected disabilities for active-duty Service Members and Veterans. Tinnitus and PTSD are highly co-morbid, yet distinct disorders. Tinnitus is an auditory disorder in which an illusory auditory percept is experienced, usually as ringing, buzzing, or whooshing sounds, despite no external objective noise source. On the other hand, PTSD is a trauma-related disorder, and is identified by intrusions of the traumatic event, avoidance of reminders, negative alterations in cognition and mood, and hypervigilance or hyperarousal. Similarities between tinnitus and PTSD have been documented among Cambodian refugees, as well as among U.S. Veteran samples. Moreover, the latest neuroimaging data from a recent clinical trial indicated that the auditory-vigilance network was the most dysregulated among active-duty service members with PTSD, compared to combat controls and civilian controls. Due to similar symptoms between tinnitus-related distress and PTSD, and similar dysregulated resting-state brain networks, it remains important to more fully understand how these two distinct disorders may be related. This study will be the first to prospectively examine the overt emotional, behavioral, and cognitive symptoms related to tinnitus-related distress and PTSD, and the overlapping functional connectivity between tinnitus and PTSD. Investigators will examine the overlapping symptoms and neurobiological mechanisms by conducting audiometric and psychological assessments and resting-state functional magnetic resonance imaging (fMRI) among 120 participants (30 with tinnitus and PTSD, 30 with only PTSD, 30 with only tinnitus, and 30 healthy controls). Participants will be recruited from the Frank Tejeda PTSD Clinic and the Audiology Clinic within the South Texas VA Health Care System, and the Hearing Center of Excellence at Lackland Air Force Base. Canonical correlations will be conducted to examine the symptom overlap between tinnitus and PTSD (Aim 1). Investigators aim to neurobiologically characterize tinnitus and PTSD, both separately and conjointly, by conducting fMRI (Aim 2). Investigators also aim to apply modeling to psychometric and neurofunctional data to identify specific regions of the auditory-vigilance network associated with distress related to tinnitus and PTSD. Understanding the shared cognitive, emotional, and behavioral symptoms and neurobiology associated with tinnitus and PTSD will help clinicians and researchers fully understand tinnitus and PTSD independently and conjointly. Results will lead to the identification of neurobiological markers for tinnitus and PTSD, identification of a different phenotype for individuals with both conditions, and development of behavioral and neuro-modulatory therapies that can reduce distress and impairment.
BACKGROUND: Interstitial lung diseases (ILDs) are a heterogeneous group of disorders, a subset of which develop progressive pulmonary fibrosis (PPF). There is little information on the epidemiology and treatment of PPFs in Japan. This retrospective cohort study estimated the incidence probability of progression to PPFs in patients with fibrosing ILDs other than idiopathic pulmonary fibrosis in a real-world Japanese setting. Management procedures and treatment patterns were also quantified.
METHODS: Data were extracted from the Medical Data Vision database from 01-Jan-2012 to 28-May-2020, comprising a 6.91-year patient identification period, 1-year pre-index period, and post-index period. The primary outcome was the cumulative incidence probability of progression to PPF up to 24 months. Subgroup analyses were performed by the presence/absence of connective tissue disease-ILD and by pre-specified ILD clinical diagnosis.
RESULTS: Of the 34,960 eligible patients (mean age: 71.1 years, males: 52.5%), 14,580 (41.7%) progressed to PPF. The 24-month incidence probability of progression to PPF was 39.5%. A relatively comparable percentage of patients progressed across all ILD subtypes. Oral corticosteroids and tacrolimus were the most common therapies during the pre- and post-index periods. Treatment rates were very low in the post-index period.
CONCLUSIONS: This is the first claims database study to estimate the incidence probability of progression to PPF in Japan. Progression appeared common in patients with chronic fibrosing ILDs, with comparable percentages of patients across all subtypes developing PPF at 2 years. Future studies should assess the impact of regular monitoring and early intervention on treating fibrotic ILDs and preventing progression.
Participants with established diagnosis of chronic GVHD and currently on treatment with ruxolitinib for chronic GVHD for at least 3 weeks. Participants in this arm are receiving ruxolitinib clinically and will not receive ruxolitinib as part of this research study.
The invention provides application of a HIF1 alpha inhibitor in preparing a medicament for treating dry senile macular degeneration. The present invention has found that HTRA1 expression in the RPE-choroid is up-regulated early in the sodium iodate-induced dry AMD mouse retinal degeneration model. HTRA1 can promote RPE cell aging by impairing mitochondrial function and activating HIF-1 signaling pathways, thereby exacerbating retinal degeneration. Cell and animal experiments show that inhibiting the HIF-1 signal channel can obviously inhibit the aging of RPE cells, thereby improving the visual function. Application of hif1α inhibitors in the manufacture of a medicament for the treatment of dry age-related macular degeneration would provide new therapeutic possibilities for dry AMD. The invention also provides application of the HIF1 alpha inhibitor in preparing a medicament for inhibiting RPE cell aging, and also provides application of the HIF1 alpha inhibitor in preparing a medicament for improving visual functions.
Because danazol may cause some degree of fluid retention, conditions that might be influenced by this factor, such as epilepsy, migraine, or cardiac or renal dysfunction, polycythemia and hypertension require careful observation. Use with caution in patients with diabetes mellitus.

Since hepatic dysfunction manifested by modest increases in serum transaminases levels has been reported in patients treated with danazol, periodic liver function tests should be performed (see and ). WARNINGSADVERSE REACTIONS

Administration of danazol has been reported to cause exacerbation of the manifestations of acute intermittent porphyria. (See .) CONTRAINDICATIONS

Laboratory monitoring of the hematologic state should be considered.
Participants received MK-8457 100 mg dosed twice daily (BID) orally with MTX at the stable dose received upon study enrollment. The Safety Extension was to last up to 76 weeks.
The present invention provides an improved pediatric formula and methods for providing nutrition to and enhancing tolerance in pediatric patients. The formula may be provided in powder, concentrate or ready to feed forms. The pediatric formula comprises, based on a 100 kcal basis, about 8 to about 16 grams carbohydrate (preferably about 9.4 to about 12.3 grams), about 3 to about 6 grams lipid (preferably about 4.7 to about 5.6 grams), about 1.8 to about 3.3 grams protein (preferably about 2.4 to about 3.3 grams), and a tolerance improver comprising about 37 to about 370 milligrams (preferably about 74 to about 222 milligrams, more preferably about 111 to about 148 milligrams) xanthan gum. The formula may also be provided in a powder, which comprises, based on 100 grams of powder, about 30 to about 90 grams carbohydrate (preferably about 48 to about 59 ), about 15 to about 30 grams lipid (preferably 22 to about 28 grams), about 8 to about 17 grams protein (preferably about 11 to about 17), and about 188 to about 1880 milligrams (preferably about 375 to about 1125, more preferably about 375 to about 1125 milligrams) xanthan gum. The formula preferably further comprises vitamins and minerals and may further comprise a stabilizer. The methods comprise administering to a pediatric patient an effective amount of a pediatric formula according to the invention, as described above.
A system for facilitating compliance and behavioral activity via signals driven by artificial intelligence is provided. In particular, the system obtains data associated with a participant from a plurality of data sources. The system may determine markers associated with the participant based on the data and may also determine a goal for the participant. The system may determine paths that the participant has taken towards the goal and may determine actions for the participant to take to advance towards the goal. The system may generate cues based on markers, the goal, the paths, segments, topics, and/or actions to motivate the participant to perform the actions. The cues are ranked and delivered to the participant based on the rank. Interactions with the cues may be monitored by the system and telemetry data relating thereto may be utilized to update artificial intelligence models of the system to enhance the cue generation process.
Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
Particular aspects provide methods for: modulating IFN-.gamma.-mediated conditions and diseases (e.g. inflammation, HIV/AIDS, etc). Additionally provided are methods for: reducing IFN-.gamma. expression or secretion in cultured mammalian cells, comprising culturing in the presence of at least one agent selected from the group consisting of estrogen, estriol, estrone and a SERM; for ex-vivo therapy for an IFN-.gamma.-mediated condition or disease, comprising culturing isolated lymphoid cells in the presence of at least one of the above agents; for treating an IFN-.gamma.-mediated condition or disease in a mammal, comprising administering to a subject at least one at least one of the above agents; for treating an IFN-.gamma.-mediated condition or disorder in a gender-dependent manner; for conferring estrogen-responsive expression using a recombinant SNP IFN-.gamma.-179G/T promoter; and for gene therapy using same. Preferably, mammalian cells are human, selected from T  cells, PBL, LPMC, and combinations thereof. In particular aspects, the cells are female.
Cigarette smoke (CS), the main source of indoor air pollution and the primary risk factor for respiratory diseases, contains chemicals that can perturb microbiota through antibiotic effects. Although smoking induces a disturbance of microbiota in the lower respiratory tract, whether and how it contributes to initiation or promotion of emphysema are not well clarified. Here, we demonstrated an aberrant microbiome in lung tissue of patients with smoking-related COPD. We found that Stenotrophomonas maltophilia (S. maltophilia) was expanded in lung tissue of patients with smoking-related COPD. We revealed that S. maltophilia drives PANoptosis in alveolar epithelial cells and represses formation of alveolar organoids through IRF1 (interferon regulatory factor 1). Mechanistically, IRF1 accelerated transcription of ZBP1 (Z-DNA Binding Protein 1) in S. maltophilia-infected alveolar epithelial cells. Elevated ZBP1 served as a component of the PANoptosome, which triggered PANoptosis in these cells. By using of alveolar organoids infected by S. maltophilia, we found that targeting of IRF1 mitigated S. maltophilia-induced injury of these organoids. Moreover, the expansion of S. maltophilia and the expression of IRF1 negatively correlated with the progression of emphysema. Thus, the present study provides insights into the mechanism of lung dysbiosis in smoking-related COPD, and presents a potential target for mitigation of COPD progression.
Evaluation of the pupillary response is an underemphasized aspect of the assessment of visual function. The pupillary light reflex is one of the few objective indicators of afferent input from the retina and optic nerve. Since the pupillary light reflex is processed through the retina, it may be used to assess visual integrity (1). Pupillometry is a reliable technology capable of providing repetitive data on quantitative pupillary function in states of health and disease (2). Amplitude, latency, maximum constriction velocity, mean constriction velocity, and dilation velocity are measured using the Neuroleptics pupillometer. The effects of varying levels of ambient light on these parameters of the pupillary response have not been extensively studied. The purpose of this investigation is to determine the effects of varying luminescent levels on the pupillary response.
Patients will receive an info letter in advance of their visit explaining the project with description of what information they will be asked to provide. Study staff will train the practice staff to hand out and collect the tablets for the patient. Staff will be trained to verify a patient's identity to ensure that the family history is sent to the correct EHR record. The initial screen of the tablet PC portal will include a paragraph of informed consent, and patients in this practice will be given the opportunity to decline participation. For patients who participate, the completed family history data will be transmitted to the patient's EHR as an HL7 compliant note and transmitting separate coded responses for each condition/ family member to coded family history fields.
The invention comprises steroids having in the A and B rings the structure <FORM:1005639/C2/1> (wherein R is alkoxy or hydroxyalkoxy and R1 is hydrogen or methyl) and their preparation by treating the corresponding 2-unsubstituted steroids with the Vilsmeier reagent followed by hydrolysis or by treating a corresponding 3,3-dialkoxy-5a -steroid saturated in ring A with not less than 2 molar equivalents of the Vilsmeier reagent followed by hydrolysis.  The reagent is prepared from formylated secondary amines and acid halides such as phosphorus halides, phosgene, thionyl chloride and oxalyl chloride. The starting materials may contain protected hydroxyl group (which may subsequently be regenerated), thiol, carbonyl, carbalkoxy, cyano, alkyl, alkenyl and alkylidene groups, lactone, ether and spiroketal residues, halogen atoms, unsaturated linkages, acylated ketol groups at most positions of the steroid nucleus and 17-side chain and a protected corticoid side chain. 16b  - Methyl - 16a ,17a  - epoxypregnen - 20 - ones are converted into the 2-formyl derivatives of 17a  - hydroxy - 16 - methylenepregnan - 20 - ones by using extra mole proportions of the reagent and 16a ,17a -epoxypregnan-20-ones are converted into 16b -halo-17a -hydroxypregnan-20-ones. Products containing a 3-formoxyalkoxy group may subsequently be hydrolysed to the required 3-hydroxyalkoxy compounds.  The preparation of a number of 2-formyl steroids of the androstane and pregnane series containing the above-mentioned groups and of the 2-for-myl-3-enol ethers of 5a -dihydrotestololactone is described and exemplified. The conversion of the products into 2-methyl-steroids; 2,3-pyrazolo-steroids and 2,3-oxazolo-steroids is also referred to.  Steroids having in the A and B rings the structure <FORM:1005639/C2/2> are prepared from the corresponding 3-ketones and the appropriate alkanols.  Steroids having in the A and B rings the structure <FORM:1005639/C2/3> are prepared either by pyrolysis of steroids of the structure VI or by catalytic hydrogenation of the corresponding 3-R-3,5-dienes; or they may be prepared in situ by treatment of steroids of the formula VI with one molar equivalent of the Vilsmeier reagent; or, when R is hydroxyalkoxy, they may also be prepared in situ by treatment of ring A saturated steroids having a 3-alkylenedioxy group with one molar equivalent of the Vilsmeier reagent.  17b -Acetoxy - 3,3 - dimethoxy - 17a  - methyl - 5a  - androstane; 17b  - acetoxy - 19 - nor - 5a  - androstan - 3 - one; 17b  - acetoxy - 17a  - methyl - 19-nor - 5a  - androstan - 3 - one; and 17b  - acetoxy - 6a ,17a  - dimethyl - 5a  - androstan - 3 - one are all prepared from the corresponding 17b -ols and acetic anhydride in pyridine.  Specification 1,005,640 is referred to.
Group A beta-hemolytic streptococcus, a common infective agent in children and adults, causes the widest range of clinical disease of any bacterium. This study is the fourth of five studies in a larger project aimed at evaluating the epidemiology of infections caused by the group A streptococcus (GAS) in Fiji. This larger project is called the Fiji Group A Streptococcal Project (Fiji GrASP). Fiji GrASP is in turn part of a larger program aimed at progression of a novel GAS vaccine - this program is the project entitled "Global GAS Vaccine Based on the M-Protein." The three broad aims of the Fiji GrASP epidemiologic studies are: (1) to establish the burden of disease of GAS infections in Fiji; (2) to describe the molecular epidemiology of GAS isolates in Fiji and; (3) to establish natural immunologic correlates of protection of a J8 vaccine if they exist. This is a cross-sectional study of 550 infants over a 2-month period. Skin will be examined for pyoderma and scabies, and swabs will be taken from pyoderma lesions once. All GAS isolates from skin swabs will undergo genetic sequencing of the N-terminal and C-repeat regions (for the J8 epitope) of the M protein at QIMR. One hundred skin swabs will undergo antimicrobial susceptibility testing against penicillin, erythromycin, clindamycin and chloramphenicol. The primary objectives of the study are to estimate the point prevalence of GAS pyoderma in 550 infants in the Central Division of Fiji and to estimate the point prevalence of scabies in 550 infants in the Central Division of Fiji. The secondary objectives of the study are to genotypically characterize group A streptococci isolated from skin swabs from pyoderma lesions in infants in Fiji and to determine antimicrobial susceptibility to penicillin, clindamycin, erythromycin and chloramphenicol in 100 GAS isolates from skin swabs. The primary endpoints of the study are to determine the number of cases of pyoderma and the number of cases of scabies. The secondary endpoints are: (1) to determine the number of children with pyoderma and scabies; (2) to determine the number of GAS isolates from skin swabs that contain the J8 epitope and the overall emm-type distribution of GAS isolates and; (3) to complete antibiograms of GAS isolates from skin to penicillin, clindamycin, erythromycin and chloramphenicol.
Patients receive acolbifene PO QD for 6 months in the absence of disease progression or unacceptable toxicity. Patients also undergo 3D mammography and collection of blood samples during screening and at the end of acolbifene treatment. In addition, patients undergo RPFNA during screening and during day 1-10 of their menstrual cycle, or if not menstruating, at the convenience of the patient and study staff.